Scarica l'app Stockscreener
105.45
1.13%
1.12
Dopo l'orario di chiusura:
103.52
-1.93
-1.83%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Gilead reports topline data from Phase III trial of Trodelvy combo therapy - Clinical Trials Arena
Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy - Baystreet.ca
Is Gilead Sciences (GILD) a Cheap NASDAQ Stock to Buy According to Hedge Funds? - Insider Monkey
Press Release Distribution & PR Platform - ACCESS Newswire
Cantor Fitzgerald maintains Overweight on Gilead with $125 target By Investing.com - Investing.com India
Gilead’s Trodelvy, With Keytruda, Slows Disease Progression in Triple-Negative Breast Cancer - BioSpace
Cantor Fitzgerald raises Gilead stock target to $125, cites HIV drug - Investing.com
Gilead Sciences (GILD) Upgraded by Cantor Fitzgerald with Positive Outlook | GILD Stock News - GuruFocus
Gilead Sciences to propel healthcare innovation and cell therapy advancement in Abu Dhabi - BioSpectrum Asia
Lobbying Update: $1,662,000 of GILEAD SCIENCES INC lobbying was just disclosed - Nasdaq
Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type - Reuters
Press Release Service: Advanced Therapy Medicinal Products Global Strategic Business Report 2025, with Profiles of Bluebird Bio, Gilead Sciences, JCR Pharmaceuticals, Kolon TissueGene, MediPost, Organogenesis and moreResearchAndMarkets.com - CRISPR Medicine News
11 Cheap NASDAQ Stocks to Buy According to Hedge Funds - Insider Monkey
Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC - insights.citeline.com
Gilead Cancer Drug Combined With Merck's Drug Effective In Difficult To Treat Type Of Breast Cancer - Benzinga
Gilead eyes earlier use of Trodelvy in TNBC as Phase III hits key goal - FirstWord Pharma
Gilead Sciences (NasdaqGS:GILD) Reveals Promising Phase 3 Trial Results For Trodelvy In mTNBC - Yahoo Finance
Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer - Fierce Pharma
Gilead Sciences (GILD) Surprises with Positive ASCENT-04 Results, Analyst Optimistic | GILD Stock News - GuruFocus
Gilead Sciences (GILD) Reports Positive Phase 3 Results for Breast Cancer Treatment | GILD Stock News - GuruFocus
Gilead's (GILD) Trodelvy Shows Promise in Breast Cancer Study - GuruFocus
Gilead Says Trodelvy-Keytruda Combination Improved Progression-Free Survival in Breast Cancer Study - marketscreener.com
Gilead Trodelvy + Merck Keytruda combo excels in first-line breast cancer - Seeking Alpha
Gilead Sciences Reports Positive Data From Phase 3 ASCENT-04/KEYNOTE-D19 Study - Nasdaq
Gilead says its therapy delayed growth of tumors in aggressive form of breast cancer - statnews.com
Gilead Sciences (GILD); Trodelvy Plus Keytruda Demonstrates Statistically Significant and Clinically Meaningful Improvement in PFS in Patients With nTNBC - StreetInsider
Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer - Business Wire
Cancer Immunotherapy Market Is Booming So Rapidly 2025-2032 - openPR.com
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences: Strong Financial Outlook and Strategic Positioning Justify Buy Rating - TipRanks
4,126,119 Shares in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Bought by Gilead Sciences Inc. - MarketBeat
Lobbying Update: $60,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings - MSN
Here's Why Gilead Sciences (GILD) is a Strong Value Stock - Yahoo Finance
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now? - MSN
BMO Capital Adjusts Gilead Sciences Price Target to $120 From $115 - marketscreener.com
Leerink Partners Adjusts Price Target on Gilead Sciences to $105 From $104, Keeps Outperform Rating - marketscreener.com
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
News - Department of Health Abu Dhabi
DoH Partners with Gilead Sciences to propel healthcare innovation and cell therapy advancement - ZAWYA
Nurix Says FDA Clears Oral IRAK4 Degrader Application for Inflammatory Diseases; Shares Up Pre-Bell - marketscreener.com
2 High-Yielding ETFs Retirees Can Safely Build Their Portfolios Around - The Motley Fool
Gilead Sciences (GILD) Stock Moves -0.74%: What You Should Know - MSN
Gilead Sciences CFO sells $266,000 in stock - Investing.com
Gilead Sciences CFO sells $266,000 in stock By Investing.com - Investing.com India
Gilead Vs Bristol Myers: Which Biotech Bigwig Is A Better Bet Now? - Barchart.com
Gilead Sciences: Advancing Oncology Care Through Gilead's Research Scholars Program - CSRwire
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN
Is Gilead Sciences Inc. (NASDAQ:GILD) the Most Undervalued Quality Stock to Buy Now? - Insider Monkey
Bridgewater Associates LP Boosts Stake in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat
11 Most Undervalued Quality Stocks to Buy Now - Insider Monkey
Lobbying Update: $75,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Nasdaq
Goldman Sachs Adjusts Price Target on Gilead Sciences to $97 From $96, Maintains Neutral Rating - MarketScreener
Revenues Working Against Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price - simplywall.st
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):